# Adipose-Derived Stem Cell Treatment Induces Early-Term Hes1 Upregulation in a Sox9- and Notch1-Independent Manner in a Rat Model of Bile Duct Ligation

**Authors:** Basri Satılmış, Egemen Çiçek, Serdar Karakaş, Koray Kutlutürk, Elif Kayhan, Mehmet Gül, Emrah Otan, Tevfik Tolga Şahin, Sezai Yılmaz

PMC · DOI: 10.3390/biomedicines14030657 · Biomedicines · 2026-03-13

## TL;DR

Adipose-derived stem cells reduce liver damage and restore function in a rat model of bile duct ligation.

## Contribution

The study shows ADSC treatment upregulates Hes1 in a Sox9- and Notch1-independent way during biliary regeneration.

## Key findings

- ADSC treatment restored liver function to sham levels in BDL rats.
- ADSC increased Hes1 gene and protein expression in early and late stages.
- ADSC reduced inflammation, fibrosis, and total damage scores in BDL rats.

## Abstract

Background/Objectives: Bile duct ligation (BDL), characterized by marked inflammation and fibrosis, effectively mimics many clinical conditions and is a valuable tool for investigating biliary regeneration. Our objective was to clarify the therapeutic benefits of adipose-derived stem cell (ADSC) treatment and signaling pathways mediating regenerative processes in a rat model of BDL. Methods: The BDL model was performed on Sprague–Dawley rats, and ADSC was administered intrasplenically at a dose of 106 cells per animal. Liver function tests, gene and protein expression analyses, histological evaluation, and immunohistochemistry staining were performed to assess liver function, signaling pathways, inflammation, and fibrosis. Results: ADSC treatment returned liver function to sham levels. ADSC upregulated the Hes1 gene and protein expression in the early and late term. Inflammation, fibrosis, and total damage scores were decreased following ADSC treatment compared with the control. Immunohistochemistry staining revealed higher CD90, CD44, and CD29 stem cell marker expression in the ADSC treatment group. Conclusions: ADSC administration reduced fibrosis and biliary damage and restored liver function, potentially in a manner mediated by upregulated Hes1 expression, supporting its promise in biliary regeneration.

## Linked entities

- **Genes:** HES1 (hes family bHLH transcription factor 1) [NCBI Gene 3280], SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662], NOTCH1 (notch receptor 1) [NCBI Gene 4851], THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960], ITGB1 (integrin subunit beta 1) [NCBI Gene 3688]

## Full-text entities

- **Genes:** Thy1 (Thy-1 cell surface antigen) [NCBI Gene 24832] {aka CD7}, Cd44 (CD44 molecule) [NCBI Gene 25406] {aka CD44A, METAA, RHAMM}, Hes1 (hes family bHLH transcription factor 1) [NCBI Gene 29577], Notch1 (notch receptor 1) [NCBI Gene 25496] {aka NOTCH, TAN1}, Sox9 (SRY-box transcription factor 9) [NCBI Gene 140586] {aka SRY}
- **Diseases:** Inflammation (MESH:D007249), biliary damage (MESH:D001660), fibrosis (MESH:D005355), Bile (MESH:D001649)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024265/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024265/full.md

## References

66 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024265/full.md

---
Source: https://tomesphere.com/paper/PMC13024265